share_log

Progyny (NASDAQ:PGNY) Updates FY 2022 Earnings Guidance

Financial News Live ·  Aug 7, 2022 19:52

Progyny (NASDAQ:PGNY – Get Rating) issued an update on its FY 2022 earnings guidance on Thursday morning. The company provided earnings per share (EPS) guidance of $0.14-$0.19 for the period, compared to the consensus estimate of $0.09. The company issued revenue guidance of $750.00 million-$775.00 million, compared to the consensus revenue estimate of $756.81 million. Progyny also updated its FY22 guidance to $0.14-$0.19 EPS.

Progyny Stock Performance

PGNY traded up $11.38 on Friday, hitting $41.15. 3,469,925 shares of the company were exchanged, compared to its average volume of 684,594. The stock has a market capitalization of $3.78 billion, a PE ratio of 89.46, a price-to-earnings-growth ratio of 21.71 and a beta of 1.85. Progyny has a 12 month low of $25.67 and a 12 month high of $68.32. The firm has a fifty day simple moving average of $30.23 and a two-hundred day simple moving average of $37.32.

Get Progyny alerts:

Progyny (NASDAQ:PGNY – Get Rating) last issued its quarterly earnings data on Thursday, August 4th. The company reported $0.09 earnings per share for the quarter, topping analysts' consensus estimates of $0.05 by $0.04. The firm had revenue of $195.00 million for the quarter, compared to analyst estimates of $190.51 million. Progyny had a return on equity of 18.11% and a net margin of 7.39%. The business's quarterly revenue was up 51.5% compared to the same quarter last year. During the same period last year, the company earned $0.19 EPS. On average, equities analysts expect that Progyny will post 0.17 earnings per share for the current year.

Insider Activity

In other Progyny news, Director Norman Payson sold 6,618 shares of Progyny stock in a transaction on Wednesday, May 11th. The stock was sold at an average price of $33.45, for a total transaction of $221,372.10. Following the completion of the transaction, the director now owns 490,828 shares in the company, valued at $16,418,196.60. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link. In related news, Director Norman Payson sold 6,618 shares of Progyny stock in a transaction on Wednesday, May 11th. The stock was sold at an average price of $33.45, for a total value of $221,372.10. Following the completion of the sale, the director now owns 490,828 shares of the company's stock, valued at $16,418,196.60. The sale was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Also, Chairman David J. Schlanger sold 1,452 shares of the business's stock in a transaction dated Monday, June 27th. The shares were sold at an average price of $31.21, for a total value of $45,316.92. Following the sale, the chairman now directly owns 82,548 shares of the company's stock, valued at approximately $2,576,323.08. The disclosure for this sale can be found here. Insiders sold a total of 41,240 shares of company stock worth $1,291,601 in the last quarter. 14.00% of the stock is owned by company insiders.

Institutional Inflows and Outflows

Several hedge funds and other institutional investors have recently bought and sold shares of PGNY. Clearbridge Investments LLC boosted its position in Progyny by 2.7% during the 1st quarter. Clearbridge Investments LLC now owns 3,223,502 shares of the company's stock valued at $165,688,000 after acquiring an additional 86,249 shares in the last quarter. State Street Corp raised its stake in shares of Progyny by 4.0% during the 1st quarter. State Street Corp now owns 2,075,678 shares of the company's stock valued at $106,690,000 after buying an additional 80,100 shares during the last quarter. Dai Ichi Life Insurance Company Ltd purchased a new position in shares of Progyny during the 1st quarter valued at about $3,069,000. Owls Nest Partners IA LLC grew its position in shares of Progyny by 9.8% during the 1st quarter. Owls Nest Partners IA LLC now owns 601,387 shares of the company's stock valued at $30,911,000 after acquiring an additional 53,836 shares during the period. Finally, Vanguard Group Inc. grew its position in shares of Progyny by 0.8% during the 1st quarter. Vanguard Group Inc. now owns 6,525,283 shares of the company's stock valued at $335,399,000 after acquiring an additional 49,779 shares during the period. Institutional investors own 82.51% of the company's stock.

About Progyny

(Get Rating)

Progyny, Inc, a benefits management company, specializes in fertility and family building benefits solutions for employers in the United States. Its fertility benefits solution includes differentiated benefits plan design, personalized concierge-style member support services, and selective network of fertility specialists.

Featured Stories

  • Get a free copy of the StockNews.com research report on Progyny (PGNY)
  • MarketBeat: Week in Review 8/1 – 8/5
  • How to Use High Beta Stocks to Maximize Your Investing Profits
  • Cronos Group Inc's Revenues Are Up, Is It Time to Buy?
  • Why Apple Could Be At All-Time Highs By Year End
  • Beyond Meat Is Not Beyond Hope, And It's Cheap

Receive News & Ratings for Progyny Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Progyny and related companies with MarketBeat.com's FREE daily email newsletter.

Disclaimer: This content is for informational and educational purposes only and does not constitute a recommendation or endorsement of any specific investment or investment strategy. Read more
    Write a comment